Kidswell Bio Corporation (TYO:4584)
Japan · Delayed Price · Currency is JPY 274.00
+9.00 (3.40%)
At close: Mar 6, 2026
Kidswell Bio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 |
Operating Revenue | 6,701 | 4,718 | 1,569 | 996 | 1,077 | 1,022 |
Other Revenue | 364 | 364 | - | - | - | - |
| 7,065 | 5,082 | 1,569 | 996 | 1,077 | 1,022 | |
Revenue Growth (YoY) | 276.40% | 223.90% | 57.53% | -7.52% | 5.41% | -3.59% |
Cost of Revenue | 5,332 | 3,649 | 551 | 120 | 654 | 412.39 |
Gross Profit | 1,732 | 1,433 | 1,018 | 876 | 423 | 609.32 |
Selling, General & Admin | 585.99 | 638 | 787 | 883 | 687 | 468.96 |
Research & Development | 896.4 | 767 | 1,150 | 963 | 898 | 945.23 |
Operating Expenses | 1,482 | 1,405 | 1,937 | 1,846 | 1,585 | 1,414 |
Operating Income | 249.98 | 28 | -919 | -970 | -1,162 | -805.17 |
Interest Expense | -37.59 | -42 | -15 | -15 | -5 | - |
Interest & Investment Income | 2.41 | - | - | - | - | 0.12 |
Currency Exchange Gain (Loss) | -98.82 | -2 | -9 | -3 | -1 | -8.34 |
Other Non Operating Income (Expenses) | -102.17 | 17 | -11 | -5 | -19 | -2.63 |
EBT Excluding Unusual Items | 13.82 | 1 | -954 | -993 | -1,187 | -816.02 |
Gain (Loss) on Sale of Investments | 35 | 35 | 417 | -7 | -145 | - |
Gain (Loss) on Sale of Assets | 4 | 4 | 2 | 1 | - | - |
Asset Writedown | 7.46 | -6 | - | -1 | -5,982 | -0.4 |
Other Unusual Items | 22.51 | 39 | 1 | - | - | -37.98 |
Pretax Income | 82.78 | 73 | -534 | -1,000 | -7,314 | -854.39 |
Income Tax Expense | 58.81 | 94 | 1 | 1 | 2 | 1.9 |
Net Income | 23.97 | -21 | -535 | -1,001 | -7,316 | -856.29 |
Net Income to Common | 23.97 | -21 | -535 | -1,001 | -7,316 | -856.29 |
Shares Outstanding (Basic) | 50 | 41 | 31 | 29 | 28 | 20 |
Shares Outstanding (Diluted) | 50 | 41 | 31 | 29 | 28 | 20 |
Shares Change (YoY) | 57.77% | 31.28% | 7.16% | 4.14% | 41.55% | 2.06% |
EPS (Basic) | 0.51 | -0.52 | -17.34 | -34.77 | -264.64 | -43.84 |
EPS (Diluted) | 0.51 | -0.52 | -17.34 | -34.77 | -264.64 | -43.84 |
Free Cash Flow | - | 930 | -1,169 | -1,267 | -1,326 | -860.32 |
Free Cash Flow Per Share | - | 22.96 | -37.89 | -44.01 | -47.97 | -44.05 |
Gross Margin | - | 28.20% | 64.88% | 87.95% | 39.28% | 59.64% |
Operating Margin | 3.54% | 0.55% | -58.57% | -97.39% | -107.89% | -78.81% |
Profit Margin | 0.34% | -0.41% | -34.10% | -100.50% | -679.29% | -83.81% |
Free Cash Flow Margin | - | 18.30% | -74.51% | -127.21% | -123.12% | -84.20% |
EBITDA | - | - | -917 | - | -1,162 | -804.85 |
EBITDA Margin | - | - | -58.45% | - | -107.86% | -78.77% |
D&A For EBITDA | - | - | 2 | - | 0.32 | 0.32 |
EBIT | 249.98 | 28 | -919 | -970 | -1,162 | -805.17 |
EBIT Margin | - | 0.55% | -58.57% | -97.39% | -107.89% | -78.81% |
Effective Tax Rate | - | 128.77% | - | - | - | - |
Revenue as Reported | - | - | - | - | - | 1,022 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.